Abbott Laboratories (ABT) vs BeOne Medicines (ONC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
BeOne Medicines (ONC) has outperformed Abbott Laboratories (ABT) over the past year, gaining 6.6% versus a loss of 25.8%. Over five years, ONC leads with a +1.6% price change compared with -16.0% for ABT. Abbott Laboratories is the larger company by market cap ($170.84 billion vs $41.41 billion), about 4.1 times the size, while BeOne Medicines is growing revenue faster (+40.2% vs +5.7%).
On valuation, Abbott Laboratories trades at a lower forward P/E (16.3x vs 35.5x for BeOne Medicines). Abbott Laboratories pays a dividend yielding 2.51%, while BeOne Medicines does not currently pay one. Abbott Laboratories converts more of its revenue into profit, with a net margin of 14.7% versus 5.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABT | ONC |
|---|---|---|
| Share price | $98.73 | $364.02 |
| Market cap | $170.84B | $41.41B |
| 1-day change | +0.58% | +0.34% |
| YTD return | -21.20% | +19.82% |
| 1-year return | -25.78% | +6.56% |
| 5-year return | -15.97% | +1.56% |
| P/E ratio (TTM) | 31.85 | 65.12 |
| Forward P/E | 16.28 | 35.49 |
| EPS (TTM) | $3.10 | $5.59 |
| Dividend yield | 2.51% | 0.00% |
| Annual dividend | $2.48 | $0.00 |
| Revenue (latest FY) | $44.33B | $5.34B |
| Revenue growth (YoY) | +5.67% | +40.23% |
| Net income (latest FY) | $6.52B | $286.93M |
| Gross margin | 56.42% | 87.49% |
| Operating margin | 18.17% | 8.37% |
| Net margin | 14.72% | 5.37% |
| 52-week high | $135.13 | $385.22 |
| 52-week low | $81.97 | $253.95 |
| Distance from 52-week high | -26.94% | -5.50% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +22.27% | +19.55% |
| Average volume | 9.56M | 391.40K |
| Shares outstanding | 1.73B | 104.92M |
| Employees | 122,000 | 12,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Abbott Laboratories is about 4.1 times larger than BeOne Medicines by market value ($170.84B vs $41.41B).
- ONC has outperformed ABT by 32.3 percentage points over the past year.
- BeOne Medicines trades at a higher earnings multiple (65.1x vs 31.8x trailing P/E).
- Abbott Laboratories offers a meaningfully higher dividend yield (2.51% vs 0.00%).
- Abbott Laboratories is more profitable, keeping 14.7 cents of every revenue dollar as net income versus 5.4 cents for BeOne Medicines.
- BeOne Medicines grew revenue faster in its latest fiscal year (+40.23% vs +5.67%).
About Abbott Laboratories
ABT stock →Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
Health Care · Biotechnology: Pharmaceutical Preparations · 122,000 employees
About BeOne Medicines
ONC stock →BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 12,000 employees
ABT vs ONC FAQ
Which is bigger, Abbott Laboratories or BeOne Medicines?
Abbott Laboratories (ABT) is larger, with a market capitalization of $170.84B compared with $41.41B for BeOne Medicines (ONC).
Which stock has performed better over the past year, ABT or ONC?
ONC returned +6.56% over the past 12 months, compared with -25.78% for ABT (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ABT or ONC?
ABT has the lower trailing P/E at 31.8, versus 65.1 for ONC. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Abbott Laboratories or BeOne Medicines?
Abbott Laboratories pays a dividend yielding 2.51%, while BeOne Medicines does not currently pay a regular dividend.
Are Abbott Laboratories and BeOne Medicines in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.